Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year?

Group 1 - Kiniksa Pharmaceuticals, Ltd. (KNSA) has shown a year-to-date return of approximately 2.5%, outperforming the Medical sector, which has seen an average loss of 7% [4] - The Zacks Consensus Estimate for KNSA's full-year earnings has increased by 182.9% over the past three months, indicating a positive trend in analyst sentiment [4] - Kiniksa Pharmaceuticals is ranked 2 (Buy) in the Zacks Rank, suggesting it is poised to outperform the broader market in the near term [3] Group 2 - Kiniksa Pharmaceuticals is part of the Medical - Biomedical and Genetics industry, which consists of 509 companies and currently ranks 85 in the Zacks Industry Rank [6] - Stocks in the Medical - Biomedical and Genetics industry have lost about 8.9% year-to-date, indicating that KNSA is performing better than its peers in this specific industry [6] - Another stock in the Medical sector, Krystal Biotech, Inc. (KRYS), has a year-to-date return of 6% and also holds a Zacks Rank of 2 (Buy) [5]